RANBAXY LAUNCHES RANTM-TAMSULOSIN HYDROCHLORIDE CAPSULES IN CANADA

Nov 21, 2007

Ranbaxy Laboratories Limited (RLL), announced today that the Company has received approval in Canada to manufacture and market Tamsulosin Hydrochloride Capsules 0.4 mg from Health Canada, Therapeutic Products Directorate (TPD). This product has proven to be bio-equivalent to Flomax® Capsules which is indicated for the treatment of Benign Prostatic Hyperplasia (BPH). The total market for both generic and brand Tamsulosin Hydrochloride Capsules in Canada is CAD $22 million (IMS-MAT: March 2007). “We are pleased to receive this approval from TPD for Tamsulosin Hydrochloride Capsules that will expand Ranbaxy’s expanding product portfolio of accessible and affordable generic product offerings. We are also quite proud of the fact that this formulation was fully developed within our parent company Ranbaxy Laboratories Limited, which further demonstrates the capabilities and competencies of the Ranbaxy organization. This is the fourth product to be added to our product portfolio through this pathway in 2007. RPCI’s Sales Team will be offering RanTM-Tamsulosin immediately under the Ranbaxy label in all of the Canadian provinces that now provides another option to pharmacist for this molecule, that will be of benefit to both patients and the Canadian Health Care system,” said Paul Drake, President, Ranbaxy Pharmaceuticals Canada Inc. (RPCI), Canada. Ranbaxy Pharmaceuticals-Canada Inc. (RPCI) based in Mississauga, Ontario, Canada, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India’s largest pharmaceutical company. RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system. Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries. *Flomax® is a registered trademark of Boehringer Ingelheim, Canada For further information please contact: Ramesh L. Adige Executive Director- Corporate Affairs and Global Corporate Communications Ranbaxy Laboratories Ltd. Plot 90, Sector 32, Gurgaon Haryana 122001, India Tel: +91-124-4135000 e-mail: ramesh.adige@ranbaxy.com or Raghu Kochar Director-Corporate Communications Ranbaxy Laboratories Ltd. Plot 90, Sector 32, Gurgaon Haryana 122001, India Tel: +91-124-4135141 Mobile: 9811617256 e-mail: raghu.kochar@ranbaxy.com or Krishnan Ramalingam Sr.Manager- Corporate Communications Plot 90, Sector 32, Gurgaon Haryana 122001, India Tel: +91-124-4135143 Mobile: 9810042540 e-mail:krishnan.ramalingam@ranbaxy.com or Paul Drake President & General Manager Ranbaxy Pharmaceuticals Canada Inc. 2680 Matheson Blvd. East Suite 200 Mississauga, ON L4W 0A5 Tel. (905) 219 8840